Innate Pharma SA
Change company Symbol lookup
Select an option...
IPHYF Innate Pharma SA
ROKU Roku Inc
HBAN Huntington Bancshares Inc
AICAF Air China Ltd
BTZ BlackRock Credit Allocation Income Trust
SLG SL Green Realty Corp
SKT Tanger Factory Outlet Centers Inc
SJR Shaw Communications Inc
SJM J M Smucker Co
SJI South Jersey Industries Inc
Go


Based in France
Company profile

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

Closing Price
$4.72
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.72
Day's Low
4.72
Volume
(Heavy Day)
Volume:
200

10-day average volume:
200
200

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of RCL, LVS and BIIB

2:01 pm ET November 18, 2020 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / November 18, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Royal Caribbean Cruises Ltd. (NYSE:RCL)Class Period: February 4, 2020 - March 17, 2020Lead Plaintiff Deadline: December 7, 2020

The RCL lawsuit alleges that throughout the class period, Royal Caribbean Cruises Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) Royal Caribbean misled investors to believe that any issue related to COVID-19 was relatively insignificant; (2) the Company falsely assured investors that bookings outside China were strong with no signs of a slowdown; (3) the Company was experiencing material declines in bookings globally due to customer concerns over COVID-19; and (5) the Company's ships were following grossly inadequate protocols that would foster the spread of COVID-19 and pose a substantial risk to passengers and crews.

Learn about your recoverable losses in RCL: http://www.kleinstocklaw.com/pslra-1/royal-caribbean-cruises-ltd-loss-submission-form?id=11040&from=1

Las Vegas Sands Corp. (NYSE:LVS)Class Period: February 27, 2016 - September 15, 2020Lead Plaintiff Deadline: December 21, 2020

Throughout the class period, Las Vegas Sands Corp. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) weaknesses existed in Marina Bay Sands' casino control measures pertaining to fund transfers; (ii) the Marina Bay Sands' casino was consequently prone to illicit fund transfers that implicated, among other issues, the transfer of customer funds to unauthorized persons and potential breaches in the Company's anti-money laundering procedures; (iii) the foregoing foreseeably increased the risk of litigation against the Company, as well as investigation and increased oversight by regulatory authorities; (iv) Las Vegas Sands had inadequate disclosure controls and procedures; (v) consequently, all the foregoing issues were untimely disclosed; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in LVS: http://www.kleinstocklaw.com/pslra-1/las-vegas-sands-corp-loss-submission-form?id=11040&from=1

Biogen Inc. (NASDAQ:BIIB)Class Period: October 22, 2019 - November 6, 2019Lead Plaintiff Deadline: January 12, 2021

The BIIB lawsuit alleges Biogen Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in BIIB: http://www.kleinstocklaw.com/pslra-1/biogen-inc-loss-submission-form?id=11040&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:J. Klein, Esq.Empire State Building350 Fifth Avenue59th FloorNew York, NY 10118jk@kleinstocklaw.comTelephone: (212) 616-4899Fax: (347) 558-9665www.kleinstocklaw.com

SOURCE: The Klein Law Firm

View source version on accesswire.com: https://www.accesswire.com/617372/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-RCL-LVS-and-BIIB

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.